The ROE as of November 2024 (TTM) for KalVista Pharmaceuticals, Inc. (KALV) is -97.37%

According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -97.37%. This represents a change of 282.03% compared to the average of -25.49% of the last 4 quarters.

KalVista Pharmaceuticals, Inc. (KALV) Historical ROE (quarterly & annually)

How has KALV ROE performed in the past?

The mean historical ROE of KalVista Pharmaceuticals, Inc. over the last ten years is -37.26%. The current -97.37% ROE has changed 161.32% with respect to the historical average. Over the past ten years (40 quarters), KALV's ROE was at its highest in in the December 2014 quarter at 10.67%. The ROE was at its lowest in in the January 2024 quarter at -32.77%.

KalVista Pharmaceuticals, Inc. (KALV) ROE by Quarter and Year

Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

KalVista Pharmaceuticals, Inc. (KALV) Average ROE

How has KALV ROE performed in the past?

The current ROE of KalVista Pharmaceuticals, Inc. (KALV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

KalVista Pharmaceuticals, Inc. (KALV) ROE vs. Peers

How is KALV’s ROE compared to its peers?

KalVista Pharmaceuticals, Inc.’s ROE is greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Kura Oncology, Inc. (-40.43%), greater than Viridian Therapeutics, Inc. (-49.65%), greater than Replimune Group, Inc. (-52.15%), greater than Nuvectis Pharma, Inc. (-152.26%), greater than Lyra Therapeutics, Inc. (-143.74%), greater than Kronos Bio, Inc. (-68.82%), greater than Gossamer Bio, Inc. (-117.33%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Cogent Biosciences, Inc. (-66.96%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Mersana Therapeutics, Inc. (-333.91%), greater than Immunocore Holdings plc (-16.68%), greater than Mirum Pharmaceuticals, Inc. (-43.47%), greater than Larimar Therapeutics, Inc. (-35.87%), less than Cytokinetics, Incorporated (196.01%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Dyne Therapeutics, Inc. (-68.85%),

Build a custom stock screener for KalVista Pharmaceuticals, Inc. (KALV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

KalVista Pharmaceuticals, Inc. (KALV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.